50090-1723 NDC - PREZCOBIX (DARUNAVIR ETHANOLATE AND COBICISTAT)

Drug Information

Product NDC: 50090-1723

Proprietary Name: PREZCOBIX

Non Proprietary Name: DARUNAVIR ETHANOLATE and COBICISTAT

Active Ingredient(s):
  • 150 mg/1 COBICISTAT;
  • 800 mg/1 DARUNAVIR ETHANOLATE


Administration Route(s): ORAL

Dosage Form(s): TABLET, FILM COATED

Pharmacy Class(es):
  • Breast Cancer Resistance Protein Inhibitors [MoA];
  • Cytochrome P450 2D6 Inhibitors [MoA];
  • Cytochrome P450 2D6 Inhibitors [MoA];
  • Cytochrome P450 3A Inhibitor [EPC];
  • Cytochrome P450 3A Inhibitors [MoA];
  • Cytochrome P450 3A Inhibitors [MoA];
  • HIV Protease Inhibitors [MoA];
  • Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA];
  • Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA];
  • Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA];
  • P-Glycoprotein Inhibitors [MoA];
  • Protease Inhibitor [EPC]

Labeler Information

Labeler Name: A-S Medication Solutions
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: NDA205395
Marketing Category: NDA
Start Marketing Date:1/31/2015

Package Information

No. Package Code Package Description Billing Unit
150090-1723-030 TABLET, FILM COATED in 1 BOTTLE (50090-1723-0)EA

NDC Record

Field Name Field Value Definition
PRODUCT NDC50090-1723The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEPREZCOBIXThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEDARUNAVIR ETHANOLATE and COBICISTATThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMETABLET, FILM COATEDThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE1/31/2015This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMENDAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERNDA205395This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEA-S Medication SolutionsName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMECOBICISTAT; DARUNAVIR ETHANOLATEAn active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH150; 800 
ACTIVE INGRED UNITmg/1; mg/1 
PHARM CLASSESBreast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], HIV Protease Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Protease Inhibitor [EPC] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 2/1/2023